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SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PM www.jacctctabstracts2014.comBackground: The new Inspiron (Scitech, Brazil) is a thin-strut (75 mm) cobalt-
chromium stent, abluminally coated with a thin (4.4 mg) PLA-PLGA polymeric layer,
eluted with low-dose sirolimus. The present study aims to evaluate the safety and
efﬁcacy proﬁle of the novel drug-eluting-stent in a very high-risk population treated in
a tertiary university hospital.
Methods: Up to May 2014, a total of 276 all-comers, without any speciﬁc anatomical
or clinical restriction, have been treated with the novel sirolimus-eluing stent im-
plantation and comprise this study population. Patients were maintained in dual an-
tiplatelet therapy for a minimum of 6 months and aspirin was prescribed indeﬁnitely
thereafter. Patients have been clinically followed-up at 1, 6 and 12 months post-
procedure.
Results: For the entire cohort, a total of 342 lesions were treated with 429
Inspiron stents. The included population had a very high risk proﬁle. Overall
53.6% were diabetics, 70.7% had multivessel disease, 39.5% were admitted with
acute coronary syndromes, heart failure was present in 16.7%, and 19.2% had
previous coronary surgery. Most lesions were type B2/C (79.8%), 31.7% were
bifurcations, and 17.6% were restenosis of a previously implanted stent. After a
mean follow-up of 136  101 days, the rate of target lesion-related death was
0.5%, myocardial infarction 4.9%, and target lesion revascularization 2.3%. There
was only one episode of (probable) stent thrombosis (total any thrombosis rate at
140 days was 0.4%).
Conclusions: The interim results of this real life registry demonstrate promising mid-
term safety and efﬁcacy results for the novel Inspiron sirolimus-eluing stent in the
treatment of highly complex patients.TCT-609
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Background: The current study aimed to compare the 1-year clinical outcomes after
implantation of the Cre8 (CID/Alvimedica, Saluggia, Italy) amphilimus, polymer-free
stent versus new generation everolimus eluting stents (EES) in a real-world patient
registry.
Methods: A total of 150 consecutive patients (197 lesions) treated with Cre8 between
January 2011 and August 2013 in 4 Italian centers were included. These were pro-
pensity matched for baseline characteristics with 150 patients (201 lesions) treated
with new generation EES during the same period. Primary outcome was one year
major adverse cardiovascular events (MACE), deﬁned as all-cause death, myocardial
infarction (MI) and target-vessel revascularization (TVR).
Results: Both groups had similar baseline characteristics including age (67.89.8
Cre8 vs. 66.99.7 EES years, p¼0.393), male gender (84% Cre8 vs. 86.7% EES,
p¼0.514) diabetes (28% Cre8 vs. 27.3% EES, p¼0.972), previous PCI (56% Cre8
vs. 58%EES, p¼0.726), previous CABG (22.0% Cre8 vs. 22.7% EES, p¼1.000)
and previous MI (33.3% Cre8 vs. 31.3% EES, p¼0.711). With regards to lesion
characteristics there was a higher prevalence of B2/C lesions in the EES group
(61.6% vs. 85.4%, P< 0.001) whereas the number of restenotic lesions was similar
(13.7% Cre8 vs. 11.0% EES, p¼0.413). Total stent length per patient
(35.425.4mm Cre8 vs. 36.626.3mm EES, p¼0.667) and SYNTAX score
(15.429.9 Cre8 vs. 15.2811.5 EES, p¼0.920) were similar in the two cohorts. At
one year, MACE rate (7.4% Cre8 vs. 10.2% EES, p¼0.261), all-cause mortality
(1.3% Cre8 vs. 1.4% EES, p¼0.823), TVR (5.2% Cre8, 8.8% EES. P¼0.169) and
target lesion revascularization-TLR (3% Cre8 vs. 7.4% EES, p¼0.108) were not
signiﬁcantly different between the two groups. There was a trend for reduced lesion
TLR at one year (3.5% Cre8, vs. 7.3% EES, p¼0.055) however this was lost after
adjustment for AHA lesion type. In patients with diabetes (Cre8 n¼42; EEE n¼41)
the 1-year TLR was 2.5% in the Cre8 group versus 14.6% in the EES group
(p¼0.056).
Conclusions: The Cre8 stent is safe and clinically effective, with similar 1-year
MACE, TVR and TLR rates as new generation EES in a “real-world” patient
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Background: The DESolve Novolimus Eluting Bioresorbable Coronary Scaffold
System (NEBCSS) is a drug-eluting bioresorbable scaffold combining a PLLA-based
scaffold coated with a biodegradable polylactide-based polymer and Novolimus, a
macrocyclic lactone mTOR inhibitor. The DESolve NX study is a prospective,
multicenter evaluation of the safety and efﬁcacy of the DESolve NEBCSS in patients
with single, de novo, native coronary artery lesions.
Methods: 126 patients receiving the study device were evaluated for multiple
clinical endpoints including: major adverse cardiac events-a composite endpoint
of cardiac death, target vessel MI, or clinically-indicated target lesion revascular-
ization, and stent thrombosis. Endpoints are assessed at 1, 6 and 12 months and
annually to 5 years. All patients underwent angiographic assessment at 6 months
with a subset of patients having IVUS and OCT at 6 months and MSCT at
12 months.
Results: Mean age at baseline was 62 years, 32% were females, and 21% diabetics.
Pre-procedure lesion length was 11.2 mm, RVD was 3.06 mm, and 18.3% of patients
had moderate-to-heavy calciﬁcation. Six-month QCA imaging demonstrated low
mean in-scaffold late lumen loss (0.20 mm), 18.3 %DS and an MLD of 2.45 mm.
Serial IVUS imaging (baseline and 6 months) demonstrated a signiﬁcant increase in
mean lumen (D 9.0%, p ¼ < 0.001) and scaffold areas (D 15.7%, p ¼ < 0.001) and
low % volume obstruction (5.05%); and serial OCT imaging demonstrated a signif-
icant increase in scaffold area (D 16.9 %, p ¼ < 0.001) and 98.78% endothelial
coverage of the scaffold at 6 months. Twelve-month MSCT results demonstrated that
lumen dimensions (21.8 %DS and 2.3mm MLD) were maintained from 6 to 12
months. Clinical events remained low (MACE ¼ 5.69% at 12 months) with no reports
of deﬁnite stent thrombosis.
Conclusions: DESolve demonstrated safety and efﬁcacy with low late lumen loss.
Serial imaging assessments indicated early vessel restoration at 6 months. At 12
months, the clinical event rate was low, and MSCT demonstrated good luminal
patency. Imaging endpoints and 2-year clinical results will be presented.TCT-611
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Background: Bioresorbable scaffold (BVS, Absorb, Abbott Vascular) are currently
used also for the treatment of acute coronary syndromes, but data on the outcome at
the level of the culprit plaque are still missing. Characteristics of a stable plaque
include a thick ﬁbrous cap and vasodilation in response to endothelium-dependent
vasodilators.
Methods: We describe the 12-months clinical, morphological and functional
outcome after BVS implantation for the treatment of culprit lesions in consecutive
patients with myocardial infarction. Vasomotion was assessed with infusions of
endothelium-dependent acetylcholine and endothelium-independent nitroglycerin.7, 2014 j TCT Abstracts/Stents - Drug-eluting: Bioresorbable Scaffolds
